

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**FIRST QUARTER**  
**2004**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	1Q `04 vs. 1Q `03					
	TOTAL % CHG	TOTAL \$ MM	U.S. % CHG	U.S. \$ MM	Foreign % CHG	Foreign \$ MM
AGGRASTAT	-2%	\$ 22	N/M	-	14%	\$ 22
ARCOXIA	*	30	-	-	*	30
CANCIDAS	89%	88	84%	49	95%	39
COZAAR / HYZAAR	-1%	629	-24%	216	19%	413
CRIXIVAN / STOCRIN	-23%	64	-84%	6	30%	58
EMEND	*	6	*	6	*	0
FOSAMAX	-4%	759	-22%	442	39%	317
INVANZ	*	12	77%	8	*	3
MAXALT	-29%	56	-49%	30	31%	26
PRIMAXIN	-8%	150	-53%	29	19%	121
PROPECIA	-4%	63	-20%	29	15%	34
PROSCAR	34%	175	48%	84	23%	91
SINGULAIR	34%	623	28%	427	48%	196
TIMOPTIC / TIMOPTIC XE	6%	37	*	2	2%	35
TRUSOPT / COSOPT	25%	131	18%	52	30%	79
VASOTEC / VASERETIC	3%	173	N/M	-	0%	173
VIOXX	30%	661	28%	386	32%	275
ZOCOR	10%	1,296	41%	900	-26%	396
HEPATITIS VACCINES	-8%	60	-5%	52	-25%	8
VIRAL VACCINES	0%	117	-3%	106	38%	11
OTHER VACCINES	-12%	52	-15%	39	-1%	12

\* > 100%

N/M - Not Meaningful

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	1Q `04	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL</b>	<u>\$ 5,631</u>	<u>1%</u>	<u>-5</u>	<u>1</u>	<u>5</u>
U.S. (\$ MM)	3,255	-5%	-9	3	0
Foreign (\$ MM)	2,376	12%	1	-2	13

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**FIRST QUARTER**  
**2004**

**OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (millions of dollars)**

	1Q `04	1Q `03
INTEREST INCOME	\$ (65.7)	\$ (87.4)
INTEREST EXPENSE	72.8	95.2
EXCHANGE (GAINS)/LOSSES	(7.8)	(7.1)
MINORITY INTERESTS	39.6	51.8
AMORTIZATION OF INTANGIBLES	37.3	31.3
Other, net	(317.0)	(36.0)
<b>TOTAL</b>	<b>\$ (240.9)</b>	<b>\$ 47.8</b>

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

<b>Merial</b>	1Q `04	1Q `03
IVOMEK, HEARTGARD, other avermectins	\$ 94	\$ 97
FRONTLINE	161	\$ 132
Biologicals	113	\$ 103
Other Animal Health	51	\$ 47
Poultry Breeding	35	\$ 38
<b>TOTAL MERIAL SALES</b>	<b>\$ 454</b>	<b>\$ 417</b>

<b>Aventis Pasteur-MSD</b>	1Q `04	1Q `03
HEPATITIS VACCINES	\$ 20	\$ 19
VIRAL VACCINES	13	11
Other Vaccines	120	90
<b>TOTAL AP-MSD SALES</b>	<b>\$ 153</b>	<b>\$ 120</b>

<b>Merck / Schering-Plough Collaboration</b>	1Q `04	1Q `03
ZETIA (Worldwide)	\$ 190	\$ 46
<b>TOTAL</b>	<b>\$ 190</b>	<b>\$ 46</b>